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Abstract
Background—Health insurance claims are a rich data source to examine medication use in 
pregnancy. Our objective was to identify pregnant women, their pregnancy outcomes, and date of 
their last menstrual period (LMP), and to estimate antidepressant dispensations in pregnancy.
Methods—From a literature search, we identified diagnosis and procedure codes indicating the 
end of a pregnancy. Using Truven Health MarketScan® Commercial Claims and Encounters 
Databases, we identified all inpatient admissions and outpatient service claims with these codes. 
We developed an algorithm to assign: (1) pregnancy outcome (ectopic pregnancy, induced or 
spontaneous abortion, live birth, or stillbirth), and (2) estimated gestational age, to each inpatient 
or outpatient visit. For each pregnancy outcome, we estimated the LMP as the admission (for 
inpatient visits) or service (for outpatient visits) date minus the gestational age. To differentiate 
visits associated with separate pregnancies, we required ≥ 2 months between one pregnancy 
outcomes and the LMP of the next pregnancy. We used this algorithm to identify pregnancies in 
2013 and to estimate the proportion of women who filled a prescription for an antidepressant from 
an outpatient pharmacy at various time points in pregnancy.
Results—We identified 488,887 pregnancies in 2013; 79% resulted in a live birth. A prescription 
for an antidepressant was filled in 6.2% of pregnancies. Dispensations varied throughout 
pregnancy and were lowest (3.1%) during the second trimester.
Conclusion—This work will inform future efforts to estimate medication dispensations during 
critical periods of preconception, interconception, and pregnancy using health insurance claims 
data.
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Estimates of the prevalence of medication use among pregnant women are limited. Most 
studies to date have relied on maternal self-reported medication use, either among mothers 
of live-born infants without congenital malformations (used as controls in case–control 
studies) or among representative samples of pregnant women (Mitchell et al., 2011; Thorpe 
et al., 2013; Tinker et al., 2015). However, maternal recall of medication use can be 
imprecise and subject to misclassification, particularly when mothers are interviewed 
months to years after early pregnancy exposures (Werler et al., 1989; Tinker et al., 2013). 
While some larger surveys, such as the National Health and Nutrition Examination Survey, 
have overcome some of these challenges by asking women about their medication use in the 
previous month and validating their responses by requesting to see a medication bottle, these 
do not allow for estimates of medication use across various time points in pregnancy (Tinker 
et al., 2015).
Access to health insurance claims data provides an opportunity to conduct studies of 
medication dispensations in pregnancy in large data sources without relying on self-report 
(Andrade et al., 2008; Huybrechts et al., 2013; Pasternak et al., 2013; Hanley and Mintzes, 
2014). However, health insurance claims data tend to lack critical pieces of information 
(e.g., estimated due date, date of last menstrual period, date of delivery) that make it difficult 
to accurately identify pregnant women, pregnancy outcomes, or estimate the gestational 
length of pregnancies. Although some researchers have overcome these challenges by 
linking maternal and infant records within the same data source (Taylor et al., 2015) or 
linking administrative claims data to vital records, electronic medical records, or other 
healthcare data (Cooper et al., 2006; Pasternak et al., 2013), these types of linkages are not 
always possible. Thus, some researchers have attempted to identify and estimate gestational 
ages of pregnancy outcomes solely from information in administrative data; many of these 
methods are well-described by Margulis and colleagues (Margulis et al., 2015). Overall, 
most previous attempts to identify pregnancies in claims data have only assessed live birth 
outcomes, assumed the same gestation for all pregnancies, or used broad estimates of 
gestational age (Margulis et al., 2015).
Our objective was to identify pregnant women, their pregnancy outcomes, and date of their 
last menstrual period (LMP) to ultimately use in analyses of medication dispensations at 
critical periods in pregnancy. A secondary objective was to use our algorithm in an analysis 
of the prevalence of antidepres-sant dispensations to pregnant women during and 
immediately before and after pregnancy.
Materials and Methods
DATA SOURCE
We used the Truven Health MarketScan® Commercial Claims and Encounters Databases for 
our analysis, a large convenience sample of individuals with employer-sponsored private 
insurance (or their spouses or dependents) (Hansen and Chang, 2011). These databases 
include inpatient and outpatient services, outpatient pharmacy prescription claims, and 
healthcare plan annual enrollment information for each enrollee followed over their period 
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of enrollment. A major strength of this data source is the ability to track individuals 
longitudinally while they are employed through the same employer, even if they switch 
health insurance plans (Hansen and Chang, 2011).
PREGNANCY ALGORITHM
We did a focused search of the literature for studies that identified deliveries, as well as other 
pregnancy outcomes, using diagnosis and procedure codes in health claims data and 
provided estimates of gestational age at the time of pregnancy outcome. Based on these 
sources (Hornbrook et al., 2007; Korelitz et al., 2013; Li et al., 2013; Likis et al., 2013), we 
developed a list of diagnosis, procedure, and Diagnosis Related Group (DRG) codes that 
signified the end of a pregnancy (Supplementary Tables A1 and A2, which are available 
online). As preterm infant codes may be included on the maternal record during the birth 
hospitalization, we included both infant and maternal diagnosis, procedure and DRG codes 
in our list. Using these sources’ gestational age assignments as a foundation, we developed 
an algorithm to assign: (1) a pregnancy outcome and (2) an estimated gestational age at the 
time when a diagnosis, procedure or DRG code was assigned. If a code did not have a 
gestational age assignment in one of the previous studies, we relied on the clinical 
(obstetrician-gynecology) expertise of one of our coauthors (E.E.P.).
Briefly, we identified all of the claims that mapped to one of the diagnosis, procedure, or 
DRG codes indicative of a pregnancy outcome, using data from inpatient and outpatient 
services files from women aged 15 to 44 years. We summarized all claims for a given visit 
and assigned a pregnancy outcome: stillbirth, live birth, induced abortion, spontaneous 
abortion, abortion of unknown type, or ectopic pregnancy. If more than one gestational age 
estimate was present, we used the minimum gestational age to avoid overestimating 
exposure during pregnancy. However, in the rare instance (less than 0.2% of all pregnancies 
included in the analysis) where a pregnant woman had multiple postterm codes (i.e., for 42 
and 43 weeks gestations, see Supplementary Table A1), we assigned 43 weeks. If a visit 
indicated a full-term delivery without a code indicating a more specific gestational age, we 
estimated that to occur at 40 weeks gestation. For each pregnancy outcome visit, we 
estimated the LMP as the admission (for inpatient visits) or service (for outpatient visits) 
date minus the estimated/assigned gestational age.
To differentiate visits associated with separate pregnancies, we first grouped all the visits 
associated with the same pregnancy outcome (stillbirth, live birth, abortions of any type 
[including induced, spontaneous, and unknown type], and ectopic pregnancy) and then 
required there to be at least 2 months between the end of one pregnancy and the beginning 
(i.e., LMP) of a subsequent pregnancy, as has been done in other studies (Devine et al., 
2010). Once this had been done for each pregnancy type, we then pooled the data from all 
pregnancy types and again required there to be at least 2 months between the end date of one 
pregnancy and the beginning (LMP) of a subsequent pregnancy.
ANALYTIC SAMPLE
We initially selected women 15 to 44 years of age at enrollment to a private health insurance 
plan in 2013. Then, using the 2013 annual enrollment file, we restricted our sample to 
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women with insurance plans that included prescription drug coverage in 2013. Using the 
aforementioned pregnancy algorithm, we identified women with end of pregnancy-related 
claims from 2013 or 2014 who were 15 to 44 years of age on their date of service and whose 
pregnancies (LMP through end of pregnancy) spanned at least 1 day in 2013. The 2012 to 
2014 annual enrollment files were used to calculate a woman’s enrollment during the 90 
days before LMP to 90 days after the end of her pregnancy or through December 31, 2014, 
whichever was earliest (as 2015 data were not yet available). We then restricted the analytic 
sample to women enrolled from the 90 days before LMP to 90 days after the end of 
pregnancy or only missing one month of enrollment during that time period and considered 
all others to be “under enrolled.” “Under enrolled” women were excluded from the analysis 
because we could not be certain that they did not fill a prescription during the study period.
ANALYSIS OF ANTIDEPRESSANT DISPENSATIONS DURING PREGNANCY
Using the RedBook™, we identified the national drug codes for antidepressant medications. 
We then identified antidepressant prescription claims from the outpatient pharmacy files for 
2012 to 2014, and calculated the proportion of 2013 pregnancies with at least one filled 
prescription for an antidepressant during the first, second, or third trimester of pregnancy or 
during the 90 days before pregnancy or the 90 days after pregnancy. As women could have 
multiple pregnancies in this time period, the unit of analysis was a pregnancy. For 
calculations of dispensations of antidepressants during the second and third trimester of 
pregnancy, we only included pregnancies that were estimated to extend at least one day into 
each of those time periods. We examined antidepressant dispensations overall, as well as by 
medication class and type.
Results
Among the approximately 10.5 million women 15 to 44 years of age enrolled in a private 
health insurance plan captured in the 2013 MarketScan® Commercial Database, 643,872 had 
either at least one end of pregnancy claim in 2013 or at least one end of pregnancy claim in 
2014 with an estimated LMP date in 2013, representing 744,630 pregnancies (Fig. 1). After 
excluding women with missing enrollment information during pregnancy or women “under-
enrolled,” there were 488,887 pregnancies to 472,341 women available for further analysis. 
The majority of these pregnancies (n = 386,127; 79.0%) were estimated to end in a live birth 
(Table 1). Among live births, 7.6% had a code for a preterm birth (<37 completed weeks 
gestation) and 13.1% had a code for a postterm (≥42 weeks completed gestation) birth.
Women filled a prescription for an antidepressant in 6.2% of pregnancies overall, though 
dispensations varied throughout pregnancy and were lowest (3.1%) during the second 
trimester (Table 2). Dispensations in the 90 days before LMP were less frequent (6.3%) than 
in the 90 days after pregnancy (8.0%). Selective serotonin reuptake inhibitors (SSRIs) were 
the most commonly dispensed class of antidepressants, with sertraline the most commonly 
dispensed medication in this class. Other commonly dispensed antidepressants (filled by 
approximately 0.9% of women during pregnancy) included other SSRIs such as citalopram, 
escitalopram, and fluoxetine, as well as an atypical antidepressant, bupropion.
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Of the 57,440 pregnancies with antidepressant dispensations at any point from the 90 days 
before LMP through 90 days after the end of pregnancy, 16,264 (28.3%) filled only one 
prescription for an antidepressant during this time period and 22,754 (39.6%) filled four or 
more. The majority of prescriptions filled (85.7%) were for a 30-day supply of medications; 
9.9% were filled for a 90-day supply. Among the 41,552 (72.4%) full- and postterm 
pregnancies (estimated as >37 weeks completed gestation) with at least one antidepressant 
dispensation, almost one-third only filled a prescription for an antidepressant in the 90 days 
after the end of their pregnancy, and 12.3% filled a prescription during each of the time 
periods assessed (Fig. 2).
Discussion
In summary, we developed an algorithm to identify pregnant women, their pregnancy 
outcomes, and estimate their gestational age and date of their LMP. We were able to 
implement this algorithm in a large (approximately 10.5 million women) dataset of 
reproductive-aged women with private health insurance. Furthermore, our algorithm allowed 
us to estimate antidepressant dispensations to pregnant women across various time points in 
pregnancy.
Overall, after restricting our sample to women with health plans including prescription drug 
coverage and sufficient enrollment before, during and after pregnancy, we identified 488,887 
pregnancies occurring in 2013. Most (79.0%) were estimated to end in live birth, 14.5% in 
spontaneous abortion, 4.1% in induced abortion, and 0.6% in stillbirth. While the overall 
proportion of live births is higher than the 75% typically reported in previous studies of 
insured populations (Manson et al., 2001; Naleway et al., 2013), it falls within the range of 
estimates (61–82%) described across various geographic areas in a study of Vaccine Safety 
Datalink data by Naleway and colleagues (Naleway et al., 2013). Compared with these 
previous studies, our estimate of induced abortions seems to be lower. This could be due to 
an error in our algorithm or because women may have chosen to pay for elective 
terminations out-of-pocket and thus these procedures would not be recorded in these 
administrative data. Additionally, our estimate could be biased due to differences in the 
geographic distribution or other sociodemographic characteristics of the population of 
women captured in MarketScan® Commercial Database (Dawson et al., 2016), as abortion 
rates vary by socioeconomic status and geographic location in the United States (Jones et al., 
2002; Pazol et al., 2015).
Among pregnancies estimated to end in a live birth, we found that 7.6% had a code for 
preterm birth and 13.1% had a code for postterm birth. Our preterm birth estimate is slightly 
lower, and postterm much higher, than those derived from obstetric estimates on birth 
certificates from the 2013 U.S. general population (9.6% and 0.41%, respectively). Postterm 
birth estimates of the 2013 general population based on birth certificate LMP estimates 
(5.5%) were much higher than the obstetric estimate and including “late term” infants (born 
at 41 weeks gestation) resulted in an estimate (14.0%) comparable to ours (Martin et al., 
2015). Thus, it is unclear if these differences are due to variations in methods used to 
estimate gestational age, slight misclassification of some of the postterm infants in our study 
(as postterm rather than “late term”) or a broader reflection of differences in socioeconomic 
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characteristics. For instance, our estimates are strikingly similar to those derived from an 
analysis of Mini-Sentinel program data, a collaboration between the U.S. Food and Drug 
Administration and administrators of 18 health plans. In those data, Andrade and colleagues 
developed an algorithm to identify pregnancies ending in live birth from April 2001 to 
December 2013 (Andrade et al., 2016). Of the 1.7 million pregnancies to women aged 10 to 
54 years in their cohort, 7.9% had a code for preterm birth and 13.3% had a code for 
postterm birth.
We estimated that women filled a prescription for an antidepressant in 6.2% of pregnancies 
overall, although dispensations varied throughout pregnancy. This estimate is similar to 
those from an analysis of the MarketScan® Commercial Database by Hanley and Mintzes, 
which was limited to the first live birth for each woman in the cohort (Hanley and Mintzes, 
2014). Their analysis consisted of 343,299 deliveries from 2006 to 2011 meeting their 
enrollment criteria, and they estimated that 6.5% of women with pregnancies ending in a live 
birth filled a prescription for an antidepressant during pregnancy. Similarly, in an analysis of 
approximately 119,000 pregnant women from seven health maintenance plan organizations 
in 2001 to 2005, Andrade and colleagues found that 6.6% of pregnant women filled a 
prescription for an antidepressant during pregnancy (Andrade et al., 2008). Antidepressant 
dispensations during pregnancy were found to be somewhat higher (8.1%) in a cohort of 1.1 
million pregnant women with Medicaid insurance (Huybrechts et al., 2013). Similar to our 
analysis, all of these studies also showed dispensations to be around 4% during the second 
and third trimesters of pregnancy. The increase in dispensations (8.0%) we observed during 
the 90 days postpartum may reflect resumption of medication use postpartum or 
identification of new postpartum depression, and the recognition of the important role of 
pharmacotherapy in its treatment (Siu et al., 2016).
Our analysis had several limitations. With respect to the development of our algorithm, the 
primary limitation is that we were unable to validate the pregnancy estimates derived from 
our pregnancy algorithm by using data from medical records or birth certificates. Thus, it is 
possible that we misclassified pregnancy outcomes, gestational length and LMP. However, 
Hornbrook et al. (2007) conducted a validation study of their algorithm compared with 
medical records abstraction using a stratified sample of approximately 500 pregnancies. That 
algorithm, which provided a basis for our algorithm, demonstrated good to excellent 
agreement on the designation and dating of pregnancy outcomes (Hornbrook et al., 2007). 
Yet the estimation of preterm birth using an algorithm based on diagnosis codes may be a bit 
more problematic.
Andrade et al. (2016) found that the positive predictive value of preterm birth diagnosis 
codes on infant records was higher (92%) than that of maternal records (76%) and that most 
maternal records do not contain infant diagnosis codes (Andrade et al., 2013). Furthermore, 
Li et al. (2013) compared gestational age estimates from their algorithm, which was a basis 
for some of the preterm codes used in our algorithm, to estimates from birth certificates and 
found that their algorithm had a 98% sensitivity for term births and 45% sensitivity for 
preterm births (Li et al., 2013). Thus, in our data, we may have underestimated the 
proportion of pregnancies ending in a preterm birth and, therefore, may have over-estimated 
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the gestational length (and opportunity for medication exposures) for some women in our 
cohort. Still, preterm births represent a small proportion of the total pregnancies in our study.
With respect to the application of the algorithm to our analysis of antidepressant 
dispensations in pregnancy, our algorithm may have misclassified the timing of medication 
dispensations, although this is less likely for chronic medications such as antidepressants as 
opposed to those used on an acute basis (Toh et al., 2008). Additionally, while our estimates 
of medication dispensations relied on pharmacy records, they did not account for inpatient 
medications or medications paid for out-of-pocket. Furthermore, while the records indicate 
that a medication prescription was filled, we cannot estimate adherence. Previous estimates 
of antidepressant adherence during pregnancy are conflicting; the proportion of pregnant 
women estimated to have low adherence ranges from 13 to 47% (Bosman et al., 2014; 
Lupattelli et al., 2015). In addition, our enrollment criteria may have further impacted the 
generalizabil-ity of our results. It is possible that women with chronic conditions are more 
likely to remain enrolled in their healthcare plan each month and thus more likely to be 
included in our study sample (Jensen et al., 2015).
Nevertheless, our analysis had multiple strengths, making it a valuable contribution to the 
literature. First, we expanded upon several previously used algorithms by including nonlive 
birth pregnancy outcomes, not requiring linkages to infant records, and using specific 
estimates of gestational age. Second, our use of this algorithm in the MarketScan® 
Commercial Database allowed for the analysis among a large cohort of pregnancies. Our 
sample size for pregnancies spanning 2013 was on par with or exceeded those derived in 
earlier studies encompassing deliveries that occurred over 5-year periods. Our large sample 
size will allow us to examine trends in medication dispensations across time and among 
rarer medication types. Lastly, our algorithm has potentially broad application and could be 
easily modified and applied to other similarly structured data sources.
In conclusion, we have developed an algorithm to identify pregnant women, their pregnancy 
outcomes, and estimate their gestational age and date of their last menstrual period. This 
work will inform future efforts to identify medication dispensations during critical periods of 
pregnancy, preconception, and the postpartum using health insurance claims data.
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Identification of Analytic Sample of Pregnancies, 2013 Truven Health MarketScan® 
Commercial Claims and Encounters Database. aNo end of pregnancy related visit or 
estimated date of last menstrual period occurring in 2013. bWomen 15 to 44 years of age at 
“end of pregnancy”-related visit. cWomen enrolled from the 90 days before the estimated 
date of last menstrual period to 90 days after the end of pregnancy or only missing one 
month of enrollment during that time period were considered sufficiently enrolled; all others 
were considered to be “under-enrolled.”
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Pattern of dispensation(s) of antide-pressant prescriptions from outpatient pharmacies, 
among pregnancies with at least 37 weeks estimated gestation (N = 41,552 pregnancies). 
Notes: X = filled a prescription for an antidepressant during this time period; LMP = Date of 
last menstrual period. aIncludes all other possible exposure combinations, each of which 
accounted for less than 2.8% of pregnancies.
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TABLE 1
Characteristics of Women and Pregnancies Included in Analysis, 2013 Truven Health MarketScan® 
Commercial Claims and Encounters Database
N (%)
Total women 472,341
Age, years (mean ± SD) 29.6 ± 5.6
Region of residence
 Northeast 80,940 (17.2%)
 North Central 104,671 (22.2%)
 South 165,536 (35.1%)
 West 108,618 (23.0%)
 Unknown 12,243 (2.6%)
Estimated to be pregnant in 2013 472,341 (100%)
Total pregnancies 488,887
 Live birth 386,127 (79.0%)
  Preterm code (<37 weeks) 29,520 (7.6%)a
  Postterm code (≥ 42 weeks) 50,749 (13.1%)a
 Spontaneous abortion 70,965 (14.5%)
 Induced abortion 20,117 (4.1%)
 Ectopic pregnancy 8,135 (1.7%)
 Stillbirthb 2,749 (0.6%)
 Abortion (unknown type) 794 (0.2%)
a
Proportion out of live births only.
b
Includes multiple gestations with one live birth and one stillbirth (n = 117).
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